Analyzing DNA methylation to understand gene regulation and disease
Official title: Sequencing of epigenetic modifications across the genome by single-molecule detection of oligonucleotide binding kinetics
Funded at Xgenomes Corp. · NIH-11185004 · Data updated 2026-11-12
This study is looking at how changes in DNA can affect health, especially for people with cancer or autoimmune diseases, and aims to develop better ways to detect these changes so that doctors can offer more accurate diagnoses and personalized treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xgenomes Corp. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | June 1, 2025 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $397,599 |
| NIH project number | 1R43HG013914-01A1 |
| Project ID | NIH-11185004 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with cancer or autoimmune diseases who are seeking advanced diagnostic options.
✕Less likely to help
Patients without any autoimmune conditions or cancer may not receive direct benefits from this research.
What this research studies
This research focuses on the analysis of DNA methylation, an important epigenetic modification that influences gene expression and genomic stability. By utilizing advanced sequencing techniques, the project aims to improve the accuracy of DNA methylation detection, which is crucial for understanding various health conditions, including cancer and autoimmune diseases. The methodology involves innovative approaches that could potentially overcome the limitations of current sequencing methods, providing more reliable data for clinical applications. Patients may benefit from enhanced diagnostic tools and personalized treatment strategies based on their unique genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnostic tools for cancer and autoimmune diseases, improving patient outcomes.
How similar studies have gone: Previous research has shown promise in improving DNA methylation analysis techniques, indicating potential for success in this novel approach.
Where this research is happening
-
Xgenomes Corp.
Cambridge, United States Active
Researchers
- Principal investigator: Mir, Kalim Ullah — Xgenomes Corp.
- Study coordinator: Mir, Kalim Ullah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.